Leon Chen

Leon Chen is currently a Board Member at Eikon Therapeutics. Prior to that, they were a Venture Partner at OrbiMed from June 2013 to September 2019. Before OrbiMed, Leon was a Partner at Skyline Ventures from August 2007 to June 2013 where they sourced, did diligence and negotiated new investments with a focus in therapeutics, life science tools and diagnostics. Leon was also a board member of Sutro Biopharma, Crescendo Biosciences and Genocea Biosciences and a Board observer at Celula and DiscoverX while at Skyline. From April 2007 to September 2007, Leon was an Entrepreneur in Residence (EIR) at Venrock where they worked on forming a new company in the field of epigenetics. Together with the team there, they evaluated relevant targets in the space that could be a focus for novel drugs in oncology. Prior to Venrock, Leon was the Founder of KAI Pharmaceuticals from January 2002 to April 2007. Before KAI Pharmaceuticals, Leon was a PhD student at Stanford from January 1998 to December 2001.

Leon Chen has a bachelors degree in biochemistry from UC Berkeley, a MBA from Stanford's Graduate School of Business, and PhDs in pharmacology and molecular pharmacology from Stanford University School of Medicine.